Measurement of CSF dynorphin A 1-8 immunoreactivity in anorexia nervosa and normal-weight bulimia.
Twenty-one patients with anorexia nervosa and 35 normal-weight patients with bulimia underwent a series of CSF studies involving measurement of CSF dynorphin A 1-8 immunoreactivity during hospitalization in an eating-disorder treatment and research program. The control group consisted of 17 healthy volunteers. There were no statistically significant differences in CSF dynorphin A 1-8 measurements among groups or within a group at various stages of treatment. These results regarding dynorphin A 1-8 immunoreactivity are discussed in light of other evidence for altered opiate function in some eating-disorder patients.
Lesem
M D
MD
Department of Psychiatry, Harris County Psychiatric Center, Houston, TX 77021.
Berrettini
W H
WH
Kaye
W H
WH
Jimerson
D C
DC
D000328:Adult; D000856:Anorexia Nervosa / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000523:psychology; D001835:Body Weight / Q000502:physiology; D001921:Brain / Q000503:physiopathology; D002032:Bulimia / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000523:psychology; D004399:Dynorphins / Q000134:cerebrospinal fluid*; D004723:Endorphins / Q000502:physiology; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales; D011957:Receptors, Opioid / Q000502:physiology
D004723:Endorphins; D010446:Peptide Fragments; D011957:Receptors, Opioid; D004399:Dynorphins; C026770:dynorphin (1-8)